MYLAN PHARMACEUTICALS INC. et al v. SANOFI-AVENTIS U.S. LLC et al
Case Number:
2:23-cv-00836
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
January 27, 2026
Mylan's Sanofi Insulin Suit Mostly Survives Dismissal Bid
A Pennsylvania federal judge Tuesday largely refused to dismiss Mylan Pharmaceuticals' antitrust lawsuit accusing Sanofi of unlawfully maintaining a monopoly in the market for injectable insulin glargine.
-
November 21, 2023
FTC Warns Of Harms In Mylan Dispute With Sanofi
Federal trade officials have said improper listings of drugs on the U.S. Food and Drug Administration's catalog of approved pharmaceuticals "can cause significant harm to competition," the latest in an intellectual property fight between Mylan Pharmaceuticals and Sanofi-Aventis.
-
September 18, 2023
Sanofi Slams Mylan's 'Mishmash' Of Claims Over Insulin
Sanofi-Aventis U.S. is asking a Pennsylvania federal court to toss Mylan Pharmaceuticals' claims that Sanofi abused discounts and patent litigation to keep Mylan's generic injectable insulin off the market, arguing Mylan's antitrust complaint amounts to a "mishmash" of allegations that fall short of pleading standards for Sherman Act suits.